Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of “Hold” by Brokerages

Posted by on Jul 8th, 2026

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) has been assigned a consensus recommendation of “Hold” from the four research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $14.50.

VRCA has been the topic of a number of research reports. Wall Street Zen upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright initiated coverage on shares of Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price on the stock.

View Our Latest Stock Report on Verrica Pharmaceuticals

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors have recently modified their holdings of VRCA. Affinity Asset Advisors LLC acquired a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth approximately $5,878,000. Armistice Capital LLC grew its holdings in Verrica Pharmaceuticals by 75.1% during the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after acquiring an additional 479,732 shares during the period. Velan Capital Investment Management LP acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $3,919,000. Boothbay Fund Management LLC bought a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter valued at about $1,210,000. Finally, Kalehua Capital Management LLC bought a new stake in shares of Verrica Pharmaceuticals during the 4th quarter valued at about $1,959,000. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $6.07 on Wednesday. The stock has a market cap of $104.28 million, a price-to-earnings ratio of -5.89 and a beta of 1.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.10 and a quick ratio of 1.98. The company has a 50 day simple moving average of $6.28 and a 200 day simple moving average of $6.44. Verrica Pharmaceuticals has a 1 year low of $3.28 and a 1 year high of $9.82.

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The firm had revenue of $5.02 million for the quarter, compared to analysts’ expectations of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. Research analysts anticipate that Verrica Pharmaceuticals will post -1.84 EPS for the current fiscal year.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

Featured Articles

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.